Last reviewed · How we verify
Placebo+ASA
Placebo+ASA is a Antiplatelet agent / NSAID Small molecule drug developed by Peking University Third Hospital. It is currently FDA-approved for Secondary prevention of cardiovascular events (myocardial infarction, stroke, transient ischemic attack), Primary prevention of cardiovascular disease in high-risk patients.
Acetylsalicylic acid (ASA) inhibits platelet aggregation by irreversibly blocking cyclooxygenase-1, reducing thromboxane A2 production and preventing clot formation.
Acetylsalicylic acid (ASA) inhibits platelet aggregation by irreversibly blocking cyclooxygenase-1, reducing thromboxane A2 production and preventing clot formation. Used for Secondary prevention of cardiovascular events (myocardial infarction, stroke, transient ischemic attack), Primary prevention of cardiovascular disease in high-risk patients.
At a glance
| Generic name | Placebo+ASA |
|---|---|
| Sponsor | Peking University Third Hospital |
| Drug class | Antiplatelet agent / NSAID |
| Target | Cyclooxygenase-1 (COX-1) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
ASA covalently acetylates cyclooxygenase-1 (COX-1) in platelets, preventing the synthesis of thromboxane A2, a potent platelet activator. This antiplatelet effect reduces the risk of thrombotic events. The placebo component serves as a control in clinical studies to isolate ASA's therapeutic benefit.
Approved indications
- Secondary prevention of cardiovascular events (myocardial infarction, stroke, transient ischemic attack)
- Primary prevention of cardiovascular disease in high-risk patients
Common side effects
- Gastrointestinal bleeding
- Dyspepsia
- Nausea
- Hemorrhagic stroke
Key clinical trials
- IRELAnD: Investigating the Role of Early Low-dose Aspirin in Diabetes (PHASE3)
- Aspirin in Preventing Colorectal Cancer in Patients With Colorectal Adenoma (PHASE2)
- The Impact of Factor Xa Inhibition on Thrombosis, Platelet Activation, and Endothelial Function in Peripheral Artery Disease (PHASE4)
- The Effect and Safety of Combined Anti-platelet Treatment in Acute Ischemic Stroke Due to Large Artery Atherosclerosis (PHASE4)
- Aspirin Continuation or Interruption in Patients at Moderate Risk for Cardiovascular Events Undergoing Colonoscopy and/or Polypectomy (PHASE3)
- REGN7508 Versus Acetylsalicylic Acid (ASA) for Venous Thromboprophylaxis After Total Knee Arthroplasty in Adult Participants (PHASE3)
- Adjuvant Low Dose Aspirin in Colorectal Cancer (PHASE3)
- Combination Antithrombotic Treatment for Prevention of Recurrent Ischemic Stroke in IntraCranial Atherosclerotic diseaSe (CATIS- ICAS) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo+ASA CI brief — competitive landscape report
- Placebo+ASA updates RSS · CI watch RSS
- Peking University Third Hospital portfolio CI
Frequently asked questions about Placebo+ASA
What is Placebo+ASA?
How does Placebo+ASA work?
What is Placebo+ASA used for?
Who makes Placebo+ASA?
What drug class is Placebo+ASA in?
What development phase is Placebo+ASA in?
What are the side effects of Placebo+ASA?
What does Placebo+ASA target?
Related
- Drug class: All Antiplatelet agent / NSAID drugs
- Target: All drugs targeting Cyclooxygenase-1 (COX-1)
- Manufacturer: Peking University Third Hospital — full pipeline
- Therapeutic area: All drugs in Cardiovascular
- Indication: Drugs for Secondary prevention of cardiovascular events (myocardial infarction, stroke, transient ischemic attack)
- Indication: Drugs for Primary prevention of cardiovascular disease in high-risk patients
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing